Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.64 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.55 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512704 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1PRMT3CASRHTT | |
| SCHEMBL10613785 | 0.81 | CASR (0.66) | ROCK2ROCK1PRMT3CASRBCAT2 | |
| SCHEMBL4525925 | 0.78 | ROCK2 (1.00) | ROCK2ROCK1HTTNAMPT | |
| SCHEMBL4531729 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL4533393 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL16227497 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL4529522 | 0.76 | ROCK2 (0.58) | ROCK2ROCK1HTTTAAR1SMN1; SMN2 | |
| SCHEMBL4529666 | 0.76 | ROCK2 (0.58) | ROCK2ROCK1HTTTAAR1SMN1; SMN2 | |
| SCHEMBL27723709 | 0.76 | ROCK2 (0.58) | ROCK2ROCK1HTTTAAR1SMN1; SMN2 | |
| SCHEMBL4511838 | 0.76 | ROCK2 (0.72) | ROCK2ROCK1CASRTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885PRMT3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.